Caribou Biosciences (CRBU) Equity Average (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Equity Average data on file, last reported at $112.1 million in Q1 2026.

• Equity Average for Q1 2026 came in at $112.1 million, down 52.32% year-over-year; the trailing twelve-month figure through Mar 2026 was $112.1 million (down 52.32% YoY), and the FY2025 annual result was $187.6 million, down 39.63% from the prior year.
• Equity Average eased to $112.1 million in Q1 2026 per CRBU's latest filing, from $132.0 million in the prior quarter.
• Over five years, Equity Average peaked at $383.3 million in Q4 2023 and troughed at $112.1 million in Q1 2026.
• A 5-year average of $278.8 million and a median of $295.8 million in 2024 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2026: Equity Average soared 1384.75% in 2022, then plunged 52.32% in 2026.
• A 5-year view of Equity Average shows it stood at $312.5 million in 2022, then rose by 22.67% to $383.3 million in 2023, then sank by 30.33% to $267.1 million in 2024, then slumped by 50.57% to $132.0 million in 2025, then slipped by 15.08% to $112.1 million in 2026.
• Business Quant data shows CRBU's Equity Average at $112.1 million in Q1 2026, $132.0 million in Q4 2025, and $154.0 million in Q3 2025.